Plant · Scientific monograph
Berberis vulgaris
Barberry / European barberry
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Glucose & Metabolic Research, Cardiovascular System, Microbial Research, Hepatic / Liver Mechanisms
Research overview
Historical use
Barberry has been used medicinally for over 2,500 years across Persia, India, China, and Europe. Ancient Egyptians used it in combination with fennel to prevent plague. In Ayurveda, Berberis aristata (closely related) is known as 'daruharidra' and used for skin conditions, eye infections, and fever. Traditional Persian and Unani medicine employed barberry bark and root for liver disease, jaundice, and as a bitter tonic. The primary alkaloid berberine was first isolated in 1826 and has since become one of the most studied plant alkaloids in pharmacology.
Modern research context
Berberine's most clinically validated application is glucose regulation. A 2015 meta-analysis of 27 RCTs (n=2,569) found berberine significantly reduced FPG, HbA1c, and HOMA-IR versus placebo, with effects comparable to metformin [1]. A systematic review and meta-analysis of 11 trials demonstrated significant LDL-C and triglyceride reduction [2]. Berberine modulates the gut microbiome, enriching short-chain fatty acid-producing bacteria (Akkermansia, Lactobacillus), which may partly explain its metabolic effects [3]. A comprehensive 2019 review confirmed efficacy in T2DM, dyslipidaemia, hypertension, and NAFLD, and documented antimicrobial activity against H. pylori, MRSA, and Candida species [4]. Human pharmacokinetic data (2018) confirm poor oral bioavailability (~5%) due to P-gp efflux and gut wall metabolism, necessitating high doses for systemic effect [5].
Adverse effects
GI side effects are the main tolerability concern: nausea, constipation, diarrhoea, and abdominal cramping — most pronounced in the first 1–2 weeks. Generally resolves with dose titration. Bitter taste. Rare: headache. Berberine crosses the placenta — contraindicated in pregnancy (neonatal jaundice risk via bilirubin displacement). Yellow discolouration of skin and mucous membranes at very high doses.
Contraindications
Contraindicated in pregnancy (risk of neonatal jaundice; bilirubin displacement from albumin in neonates). Contraindicated in neonates and infants. Caution with antidiabetic drugs (additive hypoglycaemia). Caution with CYP3A4-metabolised drugs (significant inhibition). Avoid with cyclosporin (increased plasma levels). Caution with antibiotics — berberine inhibits gut bacteria including probiotic species.
Clinical and phytochemical data
Used part
Root bark and stem bark (dried; standardised extract or isolated berberine HCl)
Primary active compounds
Berberine (isoquinoline alkaloid — primary active; 0.5–6% in bark)
Berbamine (bisbenzylisoquinoline alkaloid; immunosuppressive, anti-arrhythmic)
Oxyacanthine (bisbenzylisoquinoline alkaloid)
Palmatine and columbamine (protoberberine alkaloids)
Chelidonic acid
Tannins and resinous matter
Mechanism of action
Berberine activates AMPK (AMP-activated protein kinase) via inhibition of mitochondrial complex I, increasing AMP:ATP ratio — a mechanism shared with metformin that improves insulin sensitivity, reduces hepatic glucose output, and promotes β-oxidation of fatty acids. Inhibits PTP1B (protein tyrosine phosphatase 1B), enhancing insulin receptor signalling. Reduces LDL-cholesterol via dual mechanism: inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) transcription and upregulation of LDL receptor (LDLR) expression in hepatocytes. Antimicrobial via inhibition of bacterial DNA gyrase and topoisomerase IV. Mild inhibition of MAO-A and MAO-B may contribute to mood-stabilising effects. Modulates gut microbiome by selectively suppressing pathogenic bacteria and enriching short-chain fatty acid–producing species.
Pharmacokinetics
Absorption
Berberine is detected in human plasma after oral administration, confirming systemic absorption, but its oral bioavailability is characterised as poor due to intestinal first-pass metabolism and active efflux via P-glycoprotein and multidrug resistance proteins at the gut wall [2]. Human pharmacokinetic data were determined in 6 healthy Chinese and African volunteers who received a berberine-containing herbal preparation; berberine and its isoquinoline alkaloid relatives were quantified in plasma by LC-TOFMS [1]. Strikingly, the area under the plasma concentration-time curve (AUC) for berberine was 4–10 fold higher in African subjects compared with Chinese subjects, demonstrating pronounced inter-ethnic pharmacokinetic variability [1].
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Despite low oral bioavailability, berberine achieves tissue concentrations substantially higher than plasma levels in animal models — accumulating particularly in the liver, kidney, and intestine. These tissue-to-plasma ratios suggest that plasma levels underestimate local tissue exposure. No formal human tissue distribution studies exist.
Metabolism
In humans, berberine undergoes extensive Phase II metabolism: glucuronidation, sulfation, methylation, and demethylation are the principal biotransformation pathways identified from human plasma metabolite profiling [1]. Gut microbial metabolism also contributes, with hydroxylation, methylation, demethylation, and acetylation reactions observed in human intestinal microflora incubations [1]. Berberine is a known inhibitor of CYP3A4 in humans — demonstrated by its ability to increase ciclosporin A bioavailability in a clinical volunteer study [3] — raising the potential for herb-drug interactions when co-administered with CYP3A4 substrates.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Berberine and its conjugated metabolites are eliminated via both biliary/faecal and renal routes. Biliary excretion with enterohepatic recycling is thought to contribute to its prolonged tissue retention despite low plasma levels. Specific human half-life and urinary recovery data for berberine alone (not in multi-component formulations) have not been published.
Safety and interactions
Drug interactions
Antidiabetic agents (metformin, insulin, sulfonylureas, GLP-1 agonists) — additive glucose lowering; hypoglycaemia risk; monitor blood glucose carefully. Cyclosporin — CYP3A4 and P-gp inhibition significantly increases cyclosporin AUC; contraindicated or requires dose reduction with close monitoring. Warfarin — CYP2C9 inhibition may increase INR; monitor. Macrolide antibiotics (erythromycin, clarithromycin) — additive CYP3A4 inhibition and potential cardiac QT prolongation. Statins — berberine inhibits CYP3A4 (simvastatin, atorvastatin metabolism impaired); myopathy risk; use lower statin doses.
Toxicity
LD50 ~25 mg/kg IV in mice; >1,000 mg/kg oral (large therapeutic window by oral route). GI side effects are dose-limiting. Neonatal jaundice (kernicterus) risk — berberine displaces bilirubin from albumin in neonates with immature blood-brain barrier; never use in neonates or during pregnancy at term. High-dose cardiac effects (QT prolongation) reported in vitro at supra-therapeutic concentrations.
Special precautions
Pregnancy
Contraindicated throughout pregnancy. Berberine crosses the placenta and can cause neonatal jaundice (bilirubin displacement) and uterine contractions. Historically used as an abortifacient in traditional medicine.
Lactation
Excreted in breast milk. Contraindicated during breastfeeding — neonatal jaundice risk persists in newborns fed breast milk containing berberine.
Hepatic impairment
Hepatoprotective effects at standard doses. Severe hepatic impairment impairs CYP2D6 and CYP3A4 metabolism; berberine plasma levels may increase. Drug interaction risks amplified. Use with caution and dose reduction.
Renal impairment
No specific contraindication at therapeutic doses. Metabolites partially renally excreted; accumulation in severe CKD possible. Monitor renal function.
Sources and references
- [1] - Lan J, Zhao Y, Dong F et al., "Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.", J Ethnopharmacol, 2015, PMID: 25498346
- [2] - Dong H, Wang N, Zhao L, Lu F., "Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis.", Evid Based Complement Alternat Med, 2012, PMID: 22474388
- [3] - Liang Y, Xu X, Yin M et al., "Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis.", Endocr J, 2019, PMID: 30773536
- [4] - Imenshahidi M, Hosseinzadeh H., "Berberis Vulgaris and Berberine: An Update Review.", Phytother Res, 2019, PMID: 30880416
- [5] - Neag MA, Mocan A, Echeverría J et al., "Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders.", Front Pharmacol, 2018, PMID: 29945522